Visceral Leishmaniasis -  Awanish Kumar

Visceral Leishmaniasis (eBook)

Therapeutics and Vaccines
eBook Download: EPUB
2021 | 1. Auflage
158 Seiten
Elsevier Science (Verlag)
978-0-323-91125-2 (ISBN)
Systemvoraussetzungen
155,00 inkl. MwSt
  • Download sofort lieferbar
  • Zahlungsarten anzeigen

Visceral Leishmaniasis: Therapeutics and Vaccines describes current therapeutics, natural anti-leishmanial molecules, anti-leishmanial screening, and explores vaccine candidates and amastigote-based vaccination strategies for Leishmania. The book provides a precise view on VL, Leishmania parasite culture, host immunity and immunomodulation, natural compounds effective against VL, animal models for VL, and methodologies available for anti-leishmanial drug screening procedures against VL, as well as vaccine and vaccination-related information on Leishmaniasis.  Readers will find concrete information on past and current hurdles facing vaccine development for Leishmania, along with scientific opportunities and the potential impact of vaccines, including problems encountered.

The book is designed to increase the understanding of vaccines, particularly in VL, for students and researchers. Although vaccines are now available for many diseases, there are still challenges ahead for a vaccine for VL. The ideal vaccine must be safe and able to induce an immune response that is strong and effective. In a nutshell, a combination of chemotherapy (drugs) and immunoprophylaxis (vaccine) would be ideal to win the battle against VL.

  • Provides the first dedicated book on Visceral Leishmaniasis (VL) and anti-leishmanial screening
  • Covers major aspects of the fatal disease Visceral Leishmaniasis
  • Provides plenty of illustrations and figures
  • Includes methods of anti-leishmanial drug screening
  • Expands the perspective of readers on the complex problem of drug screening


Dr. Awanish Kumar is currently Associate Professor at the National Institute of Technology. He has a PhD in Biotechnology from the McGill University,. Canada. He is the editor of 8 books, 18 book chapters and 124 journal articles. He has 12 years of research experience and 8 years of teaching experience.
Visceral Leishmaniasis: Therapeutics and Vaccines describes current therapeutics, natural anti-leishmanial molecules, anti-leishmanial screening, and explores vaccine candidates and amastigote-based vaccination strategies for Leishmania. The book provides a precise view on VL, Leishmania parasite culture, host immunity and immunomodulation, natural compounds effective against VL, animal models for VL, and methodologies available for anti-leishmanial drug screening procedures against VL, as well as vaccine and vaccination-related information on Leishmaniasis. Readers will find concrete information on past and current hurdles facing vaccine development for Leishmania, along with scientific opportunities and the potential impact of vaccines, including problems encountered. The book is designed to increase the understanding of vaccines, particularly in VL, for students and researchers. Although vaccines are now available for many diseases, there are still challenges ahead for a vaccine for VL. The ideal vaccine must be safe and able to induce an immune response that is strong and effective. In a nutshell, a combination of chemotherapy (drugs) and immunoprophylaxis (vaccine) would be ideal to win the battle against VL. Provides the first dedicated book on Visceral Leishmaniasis (VL) and anti-leishmanial screening Covers major aspects of the fatal disease Visceral Leishmaniasis Provides plenty of illustrations and figures Includes methods of anti-leishmanial drug screening Expands the perspective of readers on the complex problem of drug screening
Erscheint lt. Verlag 25.5.2021
Sprache englisch
Themenwelt Medizin / Pharmazie Allgemeines / Lexika
Medizin / Pharmazie Medizinische Fachgebiete Onkologie
Studium Querschnittsbereiche Infektiologie / Immunologie
Naturwissenschaften Biologie
ISBN-10 0-323-91125-0 / 0323911250
ISBN-13 978-0-323-91125-2 / 9780323911252
Haben Sie eine Frage zum Produkt?
EPUBEPUB (Adobe DRM)
Größe: 7,5 MB

Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM

Dateiformat: EPUB (Electronic Publication)
EPUB ist ein offener Standard für eBooks und eignet sich besonders zur Darstellung von Belle­tristik und Sach­büchern. Der Fließ­text wird dynamisch an die Display- und Schrift­größe ange­passt. Auch für mobile Lese­geräte ist EPUB daher gut geeignet.

Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine Adobe-ID und die Software Adobe Digital Editions (kostenlos). Von der Benutzung der OverDrive Media Console raten wir Ihnen ab. Erfahrungsgemäß treten hier gehäuft Probleme mit dem Adobe DRM auf.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine Adobe-ID sowie eine kostenlose App.
Geräteliste und zusätzliche Hinweise

Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.

Mehr entdecken
aus dem Bereich
Antibiotika, Virostatika, Antimykotika, Antiparasitäre Wirkstoffe

von Hans-Reinhard Brodt; Achim Hörauf; Michael Kresken …

eBook Download (2023)
Georg Thieme Verlag KG
149,99